Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection.

Literature DB >> 24445520

Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection.

Hans-Joachim Schmoll¹, Alexander Stein².

Abstract

Entities: Disease Species

Mesh：

Year: 2014 PMID： 24445520 DOI： 10.1038/nrclinonc.2013.254

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

× No keyword cloud information.

6 in total

1. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

Authors: Jean-Yves Douillard; Kelly S Oliner; Salvatore Siena; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; Gyorgy Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean Luc Canon; Mark Rother; Richard Williams; Alan Rong; Jeffrey Wiezorek; Roger Sidhu; Scott D Patterson
Journal: N Engl J Med Date: 2013-09-12 Impact factor: 91.245

2. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Authors: Jaafar Bennouna; Javier Sastre; Dirk Arnold; Pia Österlund; Richard Greil; Eric Van Cutsem; Roger von Moos; Jose Maria Viéitez; Olivier Bouché; Christophe Borg; Claus-Christoph Steffens; Vicente Alonso-Orduña; Christoph Schlichting; Irmarie Reyes-Rivera; Belguendouz Bendahmane; Thierry André; Stefan Kubicka
Journal: Lancet Oncol Date: 2012-11-16 Impact factor: 41.316

3. A colorectal cancer classification system that associates cellular phenotype and responses to therapy.

Authors: Anguraj Sadanandam; Costas A Lyssiotis; Krisztian Homicsko; Eric A Collisson; William J Gibb; Stephan Wullschleger; Liliane C Gonzalez Ostos; William A Lannon; Carsten Grotzinger; Maguy Del Rio; Benoit Lhermitte; Adam B Olshen; Bertram Wiedenmann; Lewis C Cantley; Joe W Gray; Douglas Hanahan
Journal: Nat Med Date: 2013-04-14 Impact factor: 53.440

4. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

Authors: Hans-Joachim Schmoll; David Cunningham; Alberto Sobrero; Christos S Karapetis; Philippe Rougier; Sheryl L Koski; Ilona Kocakova; Igor Bondarenko; György Bodoky; Paul Mainwaring; Ramon Salazar; Peter Barker; Bijoyesh Mookerjee; Jane Robertson; Eric Van Cutsem
Journal: J Clin Oncol Date: 2012-09-10 Impact factor: 44.544

5. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.

Authors: Alfredo Carrato; Anna Swieboda-Sadlej; Marzanna Staszewska-Skurczynska; Robert Lim; Laslo Roman; Yaroslav Shparyk; Igor Bondarenko; Derek J Jonker; Yan Sun; Jhony A De la Cruz; J Andrew Williams; Beata Korytowsky; James G Christensen; Xun Lin; Jennifer M Tursi; Maria J Lechuga; Eric Van Cutsem
Journal: J Clin Oncol Date: 2013-01-28 Impact factor: 44.544

6. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal: Lancet Date: 2012-11-22 Impact factor: 79.321

6 in total

25 in total

1. Icaritin activates JNK-dependent mPTP necrosis pathway in colorectal cancer cells.

Authors: Chunxian Zhou; Zhengrong Chen; Xingsheng Lu; Hao Wu; Qunying Yang; Dongfeng Xu
Journal: Tumour Biol Date: 2015-10-01

2. miR-659-3p is involved in the regulation of the chemotherapy response of colorectal cancer via modulating the expression of SPHK1.

Authors: Shuyuan Li; Ying Fang; Hai Qin; Wenzheng Fu; Xipeng Zhang
Journal: Am J Cancer Res Date: 2016-09-01 Impact factor: 6.166

3. Cullin1 is a novel prognostic marker and regulates the cell proliferation and metastasis in colorectal cancer.

Authors: Weimin Wang; Yansu Chen; Jianliang Deng; Jianping Zhou; Xiancheng Gu; Yuehua Tang; Guoqiang Zhang; Yongfei Tan; Zhijun Ge; Yulin Huang; Shouyu Wang; Jianwei Zhou; Yan Zhou; Sujun Zhou
Journal: J Cancer Res Clin Oncol Date: 2015-02-05 Impact factor: 4.553

4. Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.

Authors: Lijun Wang; Yun-Rong Zhu; Shaowei Wang; Song Zhao
Journal: Tumour Biol Date: 2016-03-28

5. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.

Authors: Huang Zhijun; Wang Shusheng; Min Han; Li Jianping; Qin Li-Sen; Li Dechun
Journal: Tumour Biol Date: 2016-02-01

6. Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells.

Authors: Haizhong Huo; Zhiyuan Zhou; Jian Qin; Wenyong Liu; Bing Wang; Yan Gu
Journal: PLoS One Date: 2016-05-12 Impact factor: 3.240

7. Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.

Authors: Alexander Stein; Julia Quidde; Jan Klaus Schröder; Thomas Göhler; Barbara Tschechne; Annette-Rosel Valdix; Heinz-Gert Höffkes; Silke Schirrmacher-Memmel; Tim Wohlfarth; Axel Hinke; Andreas Engelen; Dirk Arnold
Journal: BMC Cancer Date: 2016-02-10 Impact factor: 4.430